Clinical Study on the Advantages and Disadvantages of Linear Anastomat and Tubular Anastomat in Gastrointestinal Anastomosis During Radical Gastrectomy for Distal Gastric Cancer
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 250
- 试验地点
- 1
- 主要终点
- Incidence of Intraoperative Splenic Laceration
研究概览
简要总结
The goal of this clinical trial is to observe and compare the short-term complications, long-term survival and quality of life of linear anastomat and tubular anastomat during digestive tract reconstruction after resection of distal gastric cancer.
Participants will receive a linear anastomat or tubular anastomat for digestive tract reconstruction during distal gastrectomy gastroenterostomy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≤ 18 years old ≤75 years old;
- •The primary gastric lesions were diagnosed as gastric adenocarcinoma (papillary adenocarcinoma pap, tubular adenocarcinoma tub, mucinous adenocarcinoma muc, sig-ring cell carcinoma, and poorly differentiated adenocarcinoma por) by gastroscopic biopsy.
- •The patient was clinically diagnosed with gastric cancer (in line with clinical signs of gastrointestinal reconstruction after distal subtotal gastrectomy for gastric cancer);
- •Implantation metastasis without peritoneum (confirmed by laparoscopic exploratory surgery);
- •It is estimated that R0 results can be obtained after D2 radical resection of distal gastric cancer (also applicable for multiple primary lower cancers);
- •Karnofsky score ≥60 points;
- •Preoperative ASA score: I, II, or III; 8。 Routine blood examination (no transfusion within the past 14 days) : HB≥90g/L;ANC ≥1.5×109/L;PLT ≥80×109/L;
- •Blood biochemical examination: BIL <1.5 times the upper limit of normal value (ULN);ALT and AST<2.5× ULN;Crea≤1 x ULN.
排除标准
- •Previous history of upper abdominal surgery (including gastric ESD/EMR, except laparoscopic cholecystectomy);
- •History of acute pancreatitis;
- •Preoperative imaging examination indicated fusion of enlarged lymph nodes (maximum diameter >3cm);
- •Gastric cancer patients who have received neoadjuvant therapy;
- •History of other malignant diseases within the past 5 years;
- •History of unstable angina pectoris, myocardial infarction, cerebral infarction, or cerebral hemorrhage within the past 6 months;
- •History of continuous systemic corticosteroid therapy in the past 1 month;
- •Concurrent surgical treatment for other diseases is required;
- •Patients with gastric cancer complications (bleeding, perforation) requiring emergency surgery;
- •Pyloric obstruction;
- •Lung function test FEV1< 50% of the expected value;
- •Pregnant or lactating women;
- •Suffers from severe mental illness;
- •Participate in other clinical studies at the same time;
- •Refused to sign the first round of study informed consent;
- •Unable or unwilling to comply with research requirements;
- •Patients with PD after neoadjuvant chemotherapy and unable to undergo distal gastrectomy;
- •Patients undergoing emergency surgery due to tumor bleeding, perforation and obstruction during chemotherapy.
结局指标
主要结局
Incidence of Intraoperative Splenic Laceration
时间窗: Perioperative period
The number and percentage of participants experiencing splenic laceration during surgery.
Incidence of Positive Incisal Margin
时间窗: Perioperative period
The number and percentage of participants with a positive incisal margin after tumor resection.
Incidence of Anastomosis Failure
时间窗: Perioperative period
The number and percentage of participants experiencing anastomosis failure during surgery.
次要结局
- Change in Procalcitonin Levels(Perioperative period)
- Change in C-Reactive Protein Levels(Perioperative period)
- Change in TNF-α Levels(Perioperative period)
- Change in Interleukin-6 Levels(Perioperative period)
- Health-Related Quality of Life assessed by EORTC QLQ-C30 Overall Score(3 years)
- Disease-Specific Quality of Life assessed by EORTC QLQ-STO22 Score(3 years)
